Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 6 of this Exclusive Interview, Steve asks Dr. Vinik his opinion on type 1 and SGLT-2s.
Read More »Dr. Aaron Vinik Part 5, The Hesitancy to Use New Drugs
Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 5 of this Exclusive Interview, Dr. Vinik explains the caution on the part of doctors to use the latest SGLT-2 medications despite apparent benefits.
Read More »Invokana Superior As Second Add-on to Metformin
New study indicates canagliflozin superior to glimepiride in lowering A1C.
Read More »FDA Approves Jardiance Claim to Cut Cardio Risks, Death
Guest article by David Kliff, Diabetic Investor: Panel further assessing date that SGLT-2 drug shows actual benefit for heart.
Read More »More Good News for Empagliflozin
Study announces a new benefit in addition to reductions in major adverse cardiovascular events.
Read More »EMPA-REG, the FDA, and the Future of SGLT-2s
With so much breaking news surrounding SGLT-2 Inhibitors at ADA, what conclusions can we draw? Viewpoints from our guest editorialist David Kliff, and DIC advisory board member Dr. George Bakris.
Read More »SGLT-2 Inhibitors in the Spotlight at ADA
At the 2016 conference in New Orleans, the latest research on SGLT-2 Inhibitors was on display.
Read More »NICE Backs Freer Use of SGLT-2 Inhibitors for Diabetes
The National Institute of Health and Care Excellence (NICE) has recommended that SGLT-2 inhibitors on the UK market can be used earlier in patients with diabetes
Read More »Canagliflozin Lowers BP As Well As A1C
Study shows the SGLT-2 inhibitor can lower HbA1c, BP, and weight in T2DM patients.
Read More »Canagliflozin and the Risk of Leg and Foot Amputations
FDA issues alert about interim safety results from ongoing clinical trial, but study of potential canagliflozin amputation risk is ongoing.
Read More »